INTELLIGENCE: CONGRATULATIONS TO THOSE WHO BOUGHT BIOTECH FIRM KITE PHARMA, $180 BUYOUT OFFER $KITE $GILD

INTELLIGENCE: CONGRATULATIONS TO THOSE WHO BOUGHT BIOTECH FIRM KITE PHARMA, $180 BUYOUT OFFER $KITE $GILD

This post was just published on ZYX Buy Change Alert.

 

KITE is a biotech firm focused on cancer using engineered T-cell therapy.  When The Arora Report had provided intelligence on KITE it was trading around $54.27.  Now GILD is buying it at $180.  If holding, consider taking profits and exiting the position.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of investors across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on this trade but since the entry trade was not posted here for the free subscribers in real-time but only made available to the paying subscribers, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

AFTER DOUBLING MONEY IN THIS FAMOUS BIOTECH RELATED TO APPLE, WHAT IS NEXT? $AAAP $AAPL $NEOS $NVS $PDLI $GILD $JUNO $ZIOP $BLCM $BLUE

Not long ago, French pharmaceutical company Advanced Accelerator Applications got a lot of publicity. Now it’s getting bought out. The late ...

A NEW IDEA ON UNITED THERAPEUTICS, BUYOUT RUMORS AT $200 $UTHR $GSK $GILD

This post was just published on ZYX Buy Change Alert. UTHR is a biotech company.  It closed at $127.92.  There are rumors that ...

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside ...

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely ...

ITS TIME TO LIGHTEN THE LOAD ON THESE 10 STOCKS $AAPL $AGN $GILD $ISIS $NVDA $PYPL $SBUX $NKE $SKX $TSLA

It is time to take partial profits on 10 popular stocks listed later in this column. These are great companies ...

INTELLIGENCE: CAR-T CANCER IMMUNOTHERAPY PROMISING BUYOUT TARGETS AFTER ASTRAZENECA $AZN $CLLS $JUNO $BLCM $XON $ZIOP $KITE $BLUE $ADXS $LBIO

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of ...

Follow

Get every new post delivered to your Inbox

Join other followers